Drug Profile


Alternative Names: Tabex

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Sopharma
  • Developer Achieve Pharma; National Center for Complementary and Integrative Health
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • Phase III Smoking withdrawal

Most Recent Events

  • 01 Mar 2017 Preclinical trials in Smoking withdrawal in USA (PO)
  • 01 Mar 2017 Achieve intends to file an IND application with the US FDA for Smoking withdrawal
  • 01 Mar 2017 Achieve plans a phase I trial for Smoking withdrawal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top